Printer Friendly

CRYOMEDICAL SCIENCES, INC. TERMINATES CONSULTING RELATIONSHIP WITH GARY ONIK, M.D., EFFECTIVE AT THE EXPIRATION OF ITS CURRENT TERM

 ROCKVILLE, Md., Oct. 22 /PRNewswire/ -- Cryomedical Sciences, Inc. (NASDAQ-NMS: CMSI) announced today that it has given Dr. Gary Onik notice of termination of his consultantship with the company effective at the expiration of its current term. According to J.J. Finkelstein, president and CEO: "We appreciate Dr. Onik's contributions during the development of cryosurgical techniques for liver and prostate cancer over the past three years. However, CMS is unwilling to meet his requests for increased compensation, equity and perquisites and other demands related to such a consultantship."
 Cryomedical Sciences, Inc. is engaged in the research, development, manufacture and marketing of products in the field of hypothermic (low temperature) medicine. In June 1992, CMS introduced the CMS AccuProbe(R) cryosurgical system, a device used for freezing and destroying cancer of the prostate and other organs using a minimally invasive and less expensive surgical procedure. To date, more than 1,000 procedures have been performed in the United States using the device. The company is also investigating hypothermic solutions which may permit "bloodless" surgery in the future and improve organ preservation capabilities and transplantation techniques.
 -0- 10/22/93
 /CONTACT: J.J. Finkelstein, president and CEO, of Cryomedical Sciences, 301-417-7070/
 (CMSI)


CO: Cryomedical Sciences, Inc. ST: Maryland IN: MTC SU: PER

IH-PB -- DC031 -- 5848 10/22/93 15:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 22, 1993
Words:218
Previous Article:SIGNET BANKING CORPORATION RAISES DIVIDEND 25 PERCENT
Next Article:SC BANCORP ANNOUNCES RESTRUCTURINGS AND THIRD QUARTER LOSS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters